Pharma Stock Roundup: FDA’s CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN

Pharma Stock Roundup: FDA’s CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN

Zacks

FDA rejects Merck (MRK) and AbbVie’s (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.

1 week